Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Elizabeth E. Hespenheide"'
Autor:
Oleh Haluszka, Jeffrey Williams, James T. Patrie, Stephen H. Caldwell, Lysa Woodall, Bruce D. Greenwald, Elizabeth E Hespenheide, Kenneth F. Binmoeller
Publikováno v:
The American Journal of Gastroenterology. 98:1982-1988
N-butyl-2-cyanoacrylate has been reported to be effective for bleeding varices but is not available in the United States. We report the initial US experience with cyanoacrylate in this prospective trial and evaluate its safety, efficacy, and relative
Publikováno v:
The American Journal of Gastroenterology. 97:2058-2062
OBJECTIVES: Steatosis or steatohepatitis, common conditions associated with obesity, are usually considered to be stable or only slowly progressive. We have encountered a small number of patients with a history of obesity and a subacute course of liv
Publikováno v:
Journal of Gastroenterology and Hepatology. 16:220-224
Background and Aims: Focal atrophy in primary sclerosing cholangitis (PSC) is usually thought to result from severe biliary stricture and focal biliary cirrhosis. Atrophy of the left lateral segments (segments 2 and 3) are striking when observed gros
Autor:
Emily H. Battle, Stephen H. Caldwell, Jan A. Redick, Elizabeth E Hespenheide, Julia C. Iezzoni, Bonnie L. Sheppard
Publikováno v:
American Journal of Gastroenterology. 96:519-525
OBJECTIVES: Troglitazone is a thiazolidinedione and peroxisome proliferator–activated receptor gamma (PPARγ) ligand used to treat diabetes mellitus type II. Because hyperinsulinemia may be a factor in nonalcoholic steatohepatitis (NASH), we postul
Autor:
W. Davis Parker, Russell H. Swerdlow, Elaine M. Khan, Janice K. Parks, Stephen H. Caldwell, Julia C. Iezzoni, Elizabeth E Hespenheide
Publikováno v:
Journal of Hepatology. 31:430-434
We assessed mitochondrial morphology by electron microscopy and the prevalence of a mitochondrial gene deletion in patients with non-alcoholic steatohepatitis (NASH), alcohol-related liver disease and non-fatty liver diseases. Respiratory chain funct
Autor:
Emily H. Battle, Elizabeth E Hespenheide, David H. Oelsner, Stephen H. Caldwell, Julia C. Iezzoni, Carolyn Driscoll
Publikováno v:
Hepatology. 29:664-669
We characterized 70 consecutive patients with cryptogenic cirrhosis to assess major risks for liver disease. Each patient was reevaluated for past alcohol exposure, scored by the International Autoimmune Hepatitis (IAH) score and assessed for viral h
Autor:
Jan A. Redick, Stephen H. Caldwell, Lisa Krugner-Higby, Tri H. Le, Abdullah M. S. Al-Osaimi, Elizabeth E. Hespenheide, Charissa Y. Chang, Robert K. Nakamoto, Christie Davis, Julia C. Iezzoni, Theresa C. Peterson, Anita Impaglizzo Hylton
Publikováno v:
NASH and Nutritional Therapy ISBN: 9784431213888
Nonalcoholic fatty liver (NAFL) or nonalcoholic fatty liver disease (NAFLD) as it is often called, is increasingly recognized as a common and potentially severe condition often associated with obesity, type 2 diabetes, and hyperlipidemia. The spectru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9e3e58dc9f6a3d20d7261302ad6b2d5a
https://doi.org/10.1007/4-431-27172-4_1
https://doi.org/10.1007/4-431-27172-4_1
Autor:
Stephen H. Caldwell, Tri H. Le, Bonnie L. Sheppard, Julia C. Iezzoni, Theresa C. Peterson, Elizabeth E Hespenheide, C.A. Davis, Abdullah M. S. Al-Osaimi, Kristen O. Arseneau, Jan A. Redick
Publikováno v:
Hepatology (Baltimore, Md.). 39(5)
Megamitochondria with crystalline inclusions (MMC) have been previously described in nonalcoholic fatty liver; however, their distribution within hepatic zones is unknown. We sought to determine this distribution from the core liver biopsy specimens
Publikováno v:
Pharmacoepidemiology and drug safety. 12(4)
Autor:
Vanessa M. Shami, Elizabeth E Hespenheide, Stephen J. Bickston, Stephen H. Caldwell, B. Gail Macik, Kristen O. Arseneau
Publikováno v:
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 9(2)
Severe coagulopathy in fulminant hepatic failure (FHF) is difficult to correct by conventional means. Recombinant activated factor VII (rFVIIa) is an antihemophilic factor that has shown promise in treating coagulopathy in liver disease. Our aim is t